The Global Trends in R&D report by IQVIA reveals a noteworthy trend in clinical trials participation over the past four years. In 2021, the number of participants surged to nearly 4 million, remaining impressively high at 1.9 million in 2022.

The most substantial growth has been observed in infectious disease trials. Excluding COVID-19 and Ebola studies, the number of subjects reached nearly 600,000 in 2022, showing a remarkable increase from the 125,000 recorded in 2018.

However, it’s essential to note that there was a decline in clinical trial enrollment attributed to the drop in COVID-19 trials. In 2020, these trials involved a staggering 1 million participants. While an additional 2.4 million individuals joined clinical trials in 2021, the numbers decreased, with more than 330,000 participants in 2022.

Shifting the focus to oncology trials, they accounted for 16% of all clinical trial subjects in the industry in 2022, involving 289,000 participants. This represented a slight decline of 9,000 subjects compared to the previous year but still marked an increase from the 8% share of all trial subjects in 2021.1

Access the full report here.

References

  1. Global Trends in R&D 2023. (n.d.). IQVIA. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2023

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred